Aktienanalyse zu Sensus Healthcare Inc (SRTS)SRTSSensus Healthcare Inc

Sensus Healthcare, Inc. is a medical device company. The Company is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Sensus Healthcare Inc (SRTS) is a good buy right now, trading at $3.52 with a recent RSI of 72.23 indicating strong momentum. The stock has shown a 5-day change of +5.39% and a 20-day change of +20.96%, suggesting positive short-term performance. The analyst price target of $6.50 implies a potential upside of 84.5%, which is significant. However, the main risk is the widening net loss of $8.7 million reported in Q2 2026, which raises concerns about profitability.

2 analysts cover SRTS: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.00.